The correlation of p53 protein overexpression and p53 antibodies in serum of patients with transitional cell carcinoma of the urinary bladder

Urologia Internationalis

Volumn 64, Issue 1, 2000, Pages 13-17

  Wunderlich, Heiko ^a   Hindermann, W ^a   Huller M ^a   Reichelt, O ^a   Werner, W ^a   Schubert, J ^a   Kosmehl, H ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

p53 autoantibodies; p53 protein; Transitional cell carcinoma

Indexed keywords

ALKALINE PHOSPHATASE; AUTOANTIBODY; MONOCLONAL ANTIBODY; PROTEIN ANTIBODY; PROTEIN P53;

ANTIBODY BLOOD LEVEL; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

EID: 0034007155     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030475     Document Type: Article

References (27)

1. Torti FM, Lum BL: Superficial bladder cancer. Risk of recurrence and potential role tor inteferon therapy. Cancer 1987;59:613.
2. Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang Z: Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994;152: 388-392.
3. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK: Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994;54:321-326.
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 1991;253:49-53.
5. Alfred DC, Clark GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC, Osborn CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-206.
6. Hamelin R, Laurent-Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Giroget J, Salmon RJ, Thomas G: Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:4248.
7. Lowe SW, Ruley HE, Jacks T, Houseman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;72: 637-641.
8. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B: Multifactorial analysis of p53 alteration in human cancer a review. Int J Cancer 1994; 57:19.
9. Crawford LV, Pim DC, Bulbrook RD: Detection of antibodies against cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403-408.
10. Cattoretti G, Pileri S, Parravicini C, Becker MHG, Poggi S, Bifluco C, Key G, D'Amato L, Sabattini E, Feudale E, Reynolds F, Gerdes J, Rilke F: Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 1993;171:83-98.
11. Cordell JL, Falini B, Erber WN, Gosh AK, Ahdulaizz Z, McDonald S, Pulford K, Stein H, Mason DY: Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase. J Histochem Cytochem 1984;32:219-229.
12. Gustmann C, Altmannsberger M, Osborn M, Griesser H, Feller AC: Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-Hodgkins lymphomas. Am J Pathol 1991;138:1413-1425.
13. Burkhard FC, Markwalder R, Thalmann GN, Studer UE: Immunohistochemical determination of p53 overexpression. An easy and readily available method to identify progression in superficial bladder cancer? Urol Res 1997;25:31-35.
14. Lane DP: A death in the life of p53. Nature 1993;362:786-787.
15. Lane DP: Cancer, p53 guardian of the genome. Nature 1992;358:15-16.
16. Finlay CA, Hinds PW, Tan HT, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms a hsc 70-p53 complex with altered half-time. Mol Cell Biol 1988;8:531-539.
17. al Abadi H, Nagel R, Neuhaus P: Immunohistochemical detection of p53 protein in transitional cell carcinoma of the bladder in correlation to DNA ploidy and pathohistological stage and grade. Cancer Detect Prev 1998;22(1):43-50.
18. Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, Dimopoulos MA: The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. Hum Pathol 1998;29(2):146-154.
19. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA, Bunting PS: Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994;58:480-487.
20. Huober J, Sprenger H, Costa SD, Zentgraf H, Schmid H, Kaufmann M, Bastert G: Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma (in German). Zentralbl Gynkol 1996;118(10):560-564.
21. Willsher PC, Pinder SE, Robertson L, Nicholson RI, Ellis IO, Bell JA, Blamey RW, Green JA, Robertson JF: The significance of p53 autoantibodies in the serum of patients with breast cancer. Anticancer Res 1996;16(2):927-930.
22. Angelopoulou K, Rosen B, Stratis M, Yu U, Solomon M, Diamandis EP: Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. Cancer 1996; 78(10):2146-2152.
23. Komiya T, Hirashima T, Takada M, Masuda N, Yasumitsu T, Nakagawa K, Hosono Y, Kikui M, Tsuji S, Fukoaka M, Kawase I: Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung. Anticancer Res 1997;17:3721-3724.
24. Kaur J, Srivastava A, Ralhan R: Serum p53 antibodies in patients with oral lesions: Correlation with p53/HSP70 complexes. Int J Cancer 1997;74(6):609-613.
25. Raedle J. Oremek G, Welker M, Roth WK, Caspary WF, Zeuzem S: p53-autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas 1996;13(3):241-246.
26. Maass JD, Gottschlich S, Lippert BM, Niemann AM, Gorogh T, Werner JA: Antibody formation to cellular p53 protein in patients with squamous cell carcinomas of the upper respiratory and digestive system (in German). Laryngorhinootologie 1996;75(1):53-56.
27. Lang C, Unteregger G, Kartarius S, Gunther J, Bonkhoff H, Montenarh M, Zwergel T: p53 autoantibodies in patients with urological tumours. Br J Urol 1998;82(5):721-726.